Clinical Report: Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients

Overview

This study investigates the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on lung cancer patients with hypertension receiving immune checkpoint inhibitors (ICIs). The findings suggest that ARNIs may improve survival outcomes and reduce cardiotoxicity associated with ICI therapy.

Background

The use of immune checkpoint inhibitors has significantly enhanced survival rates in cancer patients, but they are also linked to severe cardiovascular adverse events. Managing hypertension in lung cancer patients undergoing ICI therapy is crucial to mitigate these risks and ensure optimal treatment outcomes. ARNIs have shown promise in providing cardiovascular protection and may play a role in improving the safety of ICI treatments.

Data Highlights

No numerical data was provided in the source material.

Key Findings

• ARNIs may improve overall survival in lung cancer patients with hypertension undergoing ICI therapy.
• ARNIs potentially reduce the incidence of cardiotoxicity related to immune checkpoint inhibitors.
• Cardiovascular outcomes assessed included myocarditis, acute coronary syndrome, and heart failure.
• The study utilized a propensity score matching approach to ensure balanced comparison between treatment groups.
• Regular monitoring of biomarkers such as BNP and cTnI was conducted to assess heart failure and cardiotoxicity.

Clinical Implications

Healthcare professionals should consider the use of ARNIs in lung cancer patients with hypertension receiving ICIs to potentially enhance survival and reduce cardiotoxicity. Ongoing monitoring of cardiovascular health is essential during ICI therapy.

Conclusion

The findings indicate that ARNIs may offer a dual benefit of improving survival and mitigating cardiotoxicity in lung cancer patients treated with immune checkpoint inhibitors. Further studies are warranted to confirm these results.

Related Resources & Content

1. The ASCO Post, 2022 -- Incidence of Major Adverse Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors
2. The ASCO Post, 2025 -- Harm-Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer
3. The ASCO Post, 2020 -- Do HIV Positivity and Autoimmune Disease Preclude Treatment With Checkpoint Inhibitors?
4. Basic Research in Cardiology, 2024 -- Cardiovascular Adverse Events Related to Immunotherapy: An Overlooked Risk for Cancer Patients
5. 2025 ESC Guidelines for the management of myocarditis and pericarditis | European Heart Journal | Oxford Academic
6. ESH Guidelines
7. Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment - PMC
8. 2025 ESC Guidelines for the management of myocarditis and pericarditis | European Heart Journal | Oxford Academic
9. ESH Guidelines
10. Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment - PMC